Correction to: npj Breast Cancer 10.1038/s41523-023-00571-w, published online 05 August 2023
In this article the author name Scott Hoffmann, was incorrectly written as Scott Hoffman. The original article has been corrected.
. 2023 Aug 18;9:69. doi: 10.1038/s41523-023-00575-6
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft
1, Eleanor M Wigmore
2, Stuart C Williamson
1, Susana Ros
1, Cath Eberlein
1, Jennifer I Moss
1, Jelena Urosevic
1, Larissa S Carnevalli
1, Sara Talbot
1, Lauren Bradshaw
1, Catherine Blaker
1, Sreeharsha Gunda
3, Venetia Owenson
4, Scott Hoffmann
4, Daniel Sutton
4, Stewart Jones
4, Richard J A Goodwin
4, Brandon S Willis
5, Claire Rooney
6, Elza DeBruin
6, Simon T Barry
1,✉
Lorna Hopcroft
1Bioscience Early Oncology, AstraZeneca, Cambridge, UK
Find articles by Lorna Hopcroft
Eleanor M Wigmore
2Early Data Science, Oncology Data Science, AstraZeneca, Cambridge, UK
Find articles by Eleanor M Wigmore
Stuart C Williamson
1Bioscience Early Oncology, AstraZeneca, Cambridge, UK
Find articles by Stuart C Williamson
Jennifer I Moss
1Bioscience Early Oncology, AstraZeneca, Cambridge, UK
Find articles by Jennifer I Moss
Jelena Urosevic
1Bioscience Early Oncology, AstraZeneca, Cambridge, UK
Find articles by Jelena Urosevic
Larissa S Carnevalli
1Bioscience Early Oncology, AstraZeneca, Cambridge, UK
Find articles by Larissa S Carnevalli
Lauren Bradshaw
1Bioscience Early Oncology, AstraZeneca, Cambridge, UK
Find articles by Lauren Bradshaw
Catherine Blaker
1Bioscience Early Oncology, AstraZeneca, Cambridge, UK
Find articles by Catherine Blaker
Sreeharsha Gunda
3Information Technology, AstraZeneca, Chennai, Tamil Nadu India
Find articles by Sreeharsha Gunda
Richard J A Goodwin
4Imaging Sciences, AstraZeneca, Cambridge, UK
Find articles by Richard J A Goodwin
Brandon S Willis
5Bioscience Early Oncology, AstraZeneca, Boston, MA USA
Find articles by Brandon S Willis
1Bioscience Early Oncology, AstraZeneca, Cambridge, UK
2Early Data Science, Oncology Data Science, AstraZeneca, Cambridge, UK
3Information Technology, AstraZeneca, Chennai, Tamil Nadu India
4Imaging Sciences, AstraZeneca, Cambridge, UK
5Bioscience Early Oncology, AstraZeneca, Boston, MA USA
6Translational Medicine, AstraZeneca, Cambridge, UK
✉
Corresponding author.
Collection date 2023.
Subject terms: Breast cancer, Preclinical research
© The Author(s) 2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
PMCID: PMC10439172 PMID: 37596288